Thus, it is interesting to note that SGLT2 inhibitors lower BP in patients with CKD despite a blunted effect on glycosuria and urinary sodium excretion suggesting some dissociation of the natriuretic effect and BP responses to SGLT2 inhibitors. Here, SLC5A2 is linked to chronic kidney disease.